Based on what was discussed above, the exploitation of VEGFR1 as a target in CRC cells with APC mutations should lead to a better therapeutic window than VEGF-A targeting, and specific inhibition of the tumor-expressed VEGFR1 and its autocrine loops may be a yet to be explored therapeutic option. This evidence concerns the gene FLT1 and neoplasm.